Handelsavisen
prelaunch
Companies Healthcare ZJYL.O
ZJ
ZJYL.O NASDAQ Diversified Medical Equipment & Supplies

Jin Medical International Ltd

$1,93
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
2,9 %
ROE
4,0 %
Net margin
5,8 %
Debt / equity
0,64
Beta
52w range
Volume
Day range
Prev close
$2,19
Open
Next earnings
2026-11-09
Ex-dividend
TR 1Y
About

Jin Medical International Ltd provides medical equipment, supplies, and distribution services within the healthcare sector.

Business. Jin Medical International Ltd (ZJYL.O) is a healthcare services and equipment company primarily engaged in the medical equipment, supplies, and distribution industry. The firm operates on a product-sale revenue model, focusing on the provision of medical devices and related supplies. Headquartered in China, the company is listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsFY 2026 earnings (expected)2026-11-09 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
UBS Financial Services, Inc.
largest disclosed fund holder
Profitability
4,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ZJYL.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ZJYL.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsFY 2026 earnings (expected)2026-11-09 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Jin Medical International Ltd (ZJYL.O) is a healthcare services and equipment company primarily engaged in the medical equipment, supplies, and distribution industry. The firm operates on a product-sale revenue model, focusing on the provision of medical devices and related supplies. Headquartered in China, the company is listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Medical Equipment & Supplies
    AI synthesis
    GENERATED

    Jin Medical International Ltd maintains a debt-to-equity ratio of 0.64, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.86, suggesting it can cover short-term obligations but with limited buffer. However, the company's free cash flow is negative at -$5.01 million, and capital expenditures are -$6.63 million, indicating significant reinvestment in operations.

    The company's profitability is modest, with a return on equity of 4.02% and a return on assets of 2.23%. These figures are below the industry median for medical equipment and supplies firms, which typically report ROE and ROA in the 6-8% and 3-5% ranges, respectively. Gross profit of $6.04 million and operating income of $608,180 suggest a narrow margin structure, which may limit resilience during economic downturns.

    Jin Medical International Ltd's revenue is not segmented by geography or product in the available data, but the company's total revenue of $20.69 million is concentrated in a single business line. This lack of diversification increases exposure to sector-specific risks, such as regulatory changes or supply chain disruptions.

    The company's growth trajectory is uncertain, as no forward-looking revenue guidance is provided in the available data. Historical revenue figures are not available for trend analysis, but the company's operating cash flow of $2.90 million suggests some operational stability. However, the negative free cash flow and high capital expenditures indicate that the company is reinvesting heavily, which may delay near-term profitability.

    The risk assessment highlights a key liquidity flag: the company has negative net cash after subtracting total debt. This suggests a potential strain on liquidity, particularly if operating cash flow does not improve. The dilution risk is assessed as low, with no near-term pressure from share issuance or convertible debt. However, the company's capital structure includes $18.84 million in long-term debt, which could become a concern if interest rates rise or credit conditions tighten.

    Recent filings and transcripts are not available in the provided data, so no specific events can be cited. However, the company's financial snapshot indicates a need for close monitoring of liquidity and capital structure in the coming quarters.

    Key takeaways
    • Jin Medical International Ltd has a moderate debt load and a current ratio of 1.86, indicating acceptable but not robust liquidity.
    • The company's ROE and ROA are below industry medians, suggesting limited profitability and asset efficiency.
    • Revenue is not segmented, and the company operates in a single business line, increasing exposure to sector-specific risks.
    • Free cash flow is negative, and capital expenditures are high, indicating reinvestment in operations but potentially delaying profitability.
    • The company has negative net cash after subtracting total debt, raising concerns about liquidity resilience.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1,93
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $29.6M
    Net cash
    -$18.8M
    Current ratio
    1.9
    Debt / equity
    0.6
    ROA
    2.2%
    ROE
    4.0%
    Cash conversion
    244.0%
    CapEx / revenue
    -32.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Medical Equipment & Supplies259,3B node revenueABT 17,1%MDT 14,0%MDLN 11,0%SYK 9,7%BDX 8,4%HSIC 5,1%BAX 4,3%SOLV 3,2%Other 27,2%
    Source: company disclosures · own-taxonomy revenue-covered setZJYL 0,0% · rank #67 of 84

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs ZJYL · multiples and returns
    AB
    ABT
    Abbott Laboratories
    $107,13
    187,2B USD
    P/E
    26,3x
    vs self
    Div yield
    2,4 %
    vs self
    ROE
    12,5 %
    +8,5 vs self
    MD
    MDT
    Medtronic PLC
    $86,19
    110,3B USD
    P/E
    21,4x
    vs self
    Div yield
    3,4 %
    vs self
    ROE
    9,7 %
    +5,7 vs self
    MD
    MDLN
    MEDLINE INC.
    $40,47
    53,2B USD
    P/E
    202,6x
    vs self
    Div yield
    vs self
    ROE
    vs self
    SY
    SYK
    Stryker Corp
    $341,20
    131,8B USD
    P/E
    38,0x
    vs self
    Div yield
    vs self
    ROE
    13,5 %
    +9,5 vs self
    BD
    BDX
    Becton Dickinson And Co
    $170,21
    48,4B USD
    P/E
    25,6x
    vs self
    Div yield
    2,8 %
    vs self
    ROE
    7,0 %
    +2,9 vs self
    HS
    HSIC
    Henry Schein Inc
    $88,21
    10,1B USD
    P/E
    80,5x
    vs self
    Div yield
    vs self
    ROE
    3,0 %
    -1,1 vs self
    BA
    BAX
    Baxter International Inc
    $28,10
    14,5B USD
    P/E
    vs self
    Div yield
    2,3 %
    vs self
    ROE
    -15,4 %
    -19,4 vs self
    SO
    SOLV
    SOLVENTUM CORPORATION
    $76,83
    13,3B USD
    P/E
    8,6x
    vs self
    Div yield
    vs self
    ROE
    30,8 %
    +26,8 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin2,9 %Above median
    Net Margin5,8 %Above median
    ROE4,0 %Above median
    Capex / Rev-32,0 %Bottom quartile
    D/E0,64Below median
    Cash Conv2,44Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Jin Medical International Ltd Market data — financials · 2026-05-30

    Ownership & reference

    Top holders

    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • Erqi WangChairman of the Board, Chief Executive Officer

    Insider activity

    — missing data

    Short positioning

    16.2Kshares short+106.6% vs prior
    1.44days to cover
    30.8%short of daily vol
    800fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ZJYL.OCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Gross profit (YoY) (2025-09-30 vs 2024-09-30): -36.4%Derived (calculated)
    • Net margin (FY 2025-09-30): 5.8%Derived (calculated)
    • Gross margin (FY 2025-09-30): 29.2%Derived (calculated)
    • Capex (YoY) (2025-09-30 vs 2024-09-30): 4,473.9%Derived (calculated)
    • Cost of revenue (YoY) (2025-09-30 vs 2024-09-30): 4.6%Derived (calculated)
    • EPS (basic) (YoY) (2025-09-30 vs 2024-09-30): -50.0%Derived (calculated)
    • EPS (diluted) (YoY) (2025-09-30 vs 2024-09-30): -50.0%Derived (calculated)
    • Net income (YoY) (2025-09-30 vs 2024-09-30): -67.6%Derived (calculated)
    • Operating cash flow (YoY) (2025-09-30 vs 2024-09-30): 340.5%Derived (calculated)
    • Operating income (YoY) (2025-09-30 vs 2024-09-30): -83.3%Derived (calculated)
    • R&D expense (YoY) (2025-09-30 vs 2024-09-30): 4.0%Derived (calculated)
    • Revenue (YoY) (2025-09-30 vs 2024-09-30): -12.0%Derived (calculated)
    • Net income (annual): USD 1.19MSEC XBRL filing
    • Gross profit (annual): USD 6.04MSEC XBRL filing
    • Revenue (annual): USD 20.69MSEC XBRL filing
    • Capex (annual): USD 6.63MSEC XBRL filing
    • Total operating expenses (annual): USD 5.44MSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES 0SEC XBRL filing
    • Cost of revenue (annual): USD 14.64MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES 0SEC XBRL filing
    • Pre-tax income (annual): USD 1.6MSEC XBRL filing
    • Operating cash flow (annual): USD 2.9MSEC XBRL filing
    • R&D expense (annual): USD 1.56MSEC XBRL filing
    • Operating income (annual): USD 608.18KSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-11-09EVENTUpcomingFY 2026 earnings (expected) estimated date
    2026-02-10FILINGANNUAL REPORT →
    2026-01-08FILINGCURRENT REPORT →
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage